News >

Expert Emphasizes Inclusivity in Prostate Cancer Trials

Angelica Welch
Published: Wednesday, Aug 08, 2018

Daniel J. George, MD

Daniel J. George, MD
African-American men with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone acetate (Zytiga) plus prednisone in the Abi Race trial showed a longer median time to prostate-specific antigen (PSA) worsening than Caucasian patients.

In an interview with OncLive, George, a medical oncologist at Duke Cancer Center, discussed the findings from Abi Race and the implications they have on clinical trials in prostate cancer moving forward.

OncLive: Can you provide some background on the rationale for the Abi Race study?

George: In the United States, African-American men are not only at higher risk for developing prostate cancer, but they are at a much higher risk of dying from prostate cancer. In fact, they have a 2.5 times greater likelihood of death from prostate cancer than Caucasian men and are 5 times more likely to die from prostate cancer than Asian-American men.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication